
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Susceptibility and Prevention |
Authors' Affiliations: Departments of 1 Epidemiology, 2 Head and Neck Surgery, 3 Pathology, and 4 Thoracic and Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas
Requests for reprints: Qingyi Wei, Department of Epidemiology, Unit 1365, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-792-3020; Fax: 713-792-0807; E-mail: qwei{at}mdanderson.org.
Purpose: Alteration of the FAS/FAS ligand (FASLG) pathway regulating cell death may lead to cancer development, but the effects of functional promoter polymorphisms of the FAS and FASLG genes on risk of squamous cell carcinoma of the head and neck (SCCHN) are unknown.
Design: We genotyped the FAS 1377 G>A, FAS 670 A>G, FASLG 844 C>T, and FASLG IVS2nt 124 A>G polymorphisms in 721 case patients with SCCHN and 1,234 cancer-free nonHispanic White control subjects frequency-matched by age and sex. Multivariate logistic regression was used to assess the adjusted odds ratios (OR) and 95% confidence intervals (CI).
Results: Compared with the FAS 1377 GG and 670 AA genotypes, the FAS 1377 AA and 670 (GG + AG) genotypes were associated with an increased risk of SCCHN (OR, 2.23; 95% CI, 1.07-4.64 and OR, 1.24; 95% CI, 1.01-1.52, respectively), whereas no risk of SCCHN was associated with any of the FASLG genotypes. When we used the combined FAS 1377 (GG + AG)/670 AA genotypes as the reference, we found that the individuals carrying the FAS 1377 AA/670 (GG + AG) had the highest risk (OR, 2.69; 95% CI, 1.24-5.83), whereas individuals carrying genotypes other than FAS 1377 (GG + AG)/670 AA had a higher risk of SCCHN (OR, 1.24; 95% CI, 1.01-1.52). Furthermore, the elevated risk was particularly evident for pharyngeal cancer with the larger tumors without regional lymph metastasis (OR, 1.77; 95% CI, 1.07-2.94).
Conclusions: The FAS (but not FASLG) polymorphisms seem to contribute to risk of developing SCCHN, particularly the pharyngeal cancer in nonHispanic Whites. However, potential selection bias warrants future population-based studies to verify the findings.
This article has been cited by other articles:
![]() |
M. Yang, T. Sun, L. Wang, D. Yu, X. Zhang, X. Miao, J. Liu, D. Zhao, H. Li, W. Tan, et al. Functional Variants in Cell Death Pathway Genes and Risk of Pancreatic Cancer Clin. Cancer Res., May 15, 2008; 14(10): 3230 - 3236. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Greeneltch, M. Schneider, S. M. Steinberg, D. J. Liewehr, T. J. Stewart, K. Liu, and S. I. Abrams Host Immunosurveillance Controls Tumor Growth via IFN Regulatory Factor-8 Dependent Mechanisms Cancer Res., November 1, 2007; 67(21): 10406 - 10416. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Gillenwater, M. Zhong, and R. Lotan Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells Mol. Cancer Ther., November 1, 2007; 6(11): 2967 - 2975. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Li, L.-E Wang, P. Chang, A. K. El-Naggar, E. M. Sturgis, and Q. Wei In vitro Benzo[a]pyrene Diol Epoxide-Induced DNA Adducts and Risk of Squamous Cell Carcinoma of Head and Neck Cancer Res., June 15, 2007; 67(12): 5628 - 5634. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |